Hydrocortisone Dosing during Puberty in Patients with Classical Congenital Adrenal Hyperplasia: An Evidence-Based Recommendation
The DOI matches its Crossref record; 39 of the 41 references it cites were found in a registry or an index.
Abstract
CONTEXT: Patients with congenital adrenal hyperplasia (CAH) are at risk for early pubertal development and diminished pubertal growth. Liberal treatment with glucocorticoids will prevent early puberty but may inhibit growth outright. OBJECTIVE: The aim of the study was to determine an optimal range for hydrocortisone dosing during puberty in children with classical CAH who were exclusively treated with hydrocortisone. METHODS: The effects of glucocorticoid treatment for classical CAH were retrospectively analyzed in 92 patients (57 females). Growth pattern, final height (FH), and mean daily hydrocortisone dose were recorded. RESULTS: Pubertal growth was significantly reduced in all patients: salt-wasting (SW) females, 13.8 +/- 7.4 cm; simple virilizing (SV) females, 13.1 +/- 6.2 cm; vs. reference, 20.3 +/- 6.8 cm (P < 0.05); and SW males, 17.7 +/- 6.7 cm; SV males, 16.2 +/- 5.7 cm; vs. reference, 28.2 +/- 8.2 cm (P < 0.05). Decreased pubertal growth resulted in FH at the lower limit of genetic potential (corrected FH in SW females, -0.6 +/- 0.9; SV females, -0.3 +/- 0.9; SW males, -0.8 +/- 0.8; and SV males, -1.0 +/- 1.0). During puberty, mean daily hydrocortisone dose was 17.2 +/- 3.4 mg/m(2) in females (SW, 17.0 +/- 3.3; SV, 17.4 +/- 3.5) and 17.9 +/- 2.5 mg/m(2) in males (SW, 17.4 +/- 2.0; SV, 18.7 +/- 3.1). In a logistic regression model, a significant correlation between hydrocortisone dose and FH was found (P < 0.01), and the positive predictive value for short stature rose from below 30% to above 60% when hydrocortisone dose exceeded 17 mg/m(2). CONCLUSION: With conventional hydrocortisone treatment, pubertal growth is significantly reduced in both sexes, resulting in a FH at the lower limit of genetic potential. These deleterious effects on pubertal growth can be reduced if hydrocortisone does not exceed 17 mg/m(2).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with CAH, glucocorticoid dosages exceeding 20 mg/m 2 /d in infants and 15 to 17 mg/m 2 /d in adolescents have been shown to result in loss of height and shorter adult stature (124, 125).”
From Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [124]
In the citing paper
“When doses exceed 20 mg/m 2 per day in infants or 15 to 17 mg/m 2 per day in adolescents, there is a decrease in height standard deviation score (SDS), leading to a decreased adult height SDS (196)(197)(198)(199).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [197]
Citations
Cites
RADIOGRAPHIC ATLAS OF SKELETAL DEVELOPMENT OF THE HAND AND WRIST
GREULICH, W. W., & PYLE, S. I. (1959) · The American Journal Of The Medical Sciences · doi:10.1097/00000441-195909000-00030 · Cited by 5,585
Body mass index reference curves for the UK, 1990.
Cole, T. J., Freeman, J. V., & Preece, M. A. (1995) · Archives of Disease in Childhood · doi:10.1136/adc.73.1.25 · Cited by 2,047
Congenital Adrenal Hyperplasia
(1987) · New England Journal of Medicine · doi:10.1056/nejm198711263172211 · Cited by 1,409
Congenital adrenal hyperplasia
Speiser, P. W., & White, P. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021561 · Cited by 1,405
Prader, A., Largo, R. H., Molinari, L., & Issler, C. (1989) · PubMed · Cited by 814
(2002) · Hormone Research in Paediatrics · doi:10.1159/000065490 · Cited by 458
Krone, N., Braun, A., Roscher, A. A., Knorr, D., & Schwarz, H. P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.3.6441 · Cited by 397
Self-citationMulaikal, R. M., Migeon, C. J., & Rock, J. A. (1987) · New England Journal of Medicine · doi:10.1056/nejm198701223160402 · Cited by 361
Joint LWPES/ESPE CAH Working Group (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020611 · Cited by 332
Pubertal development in Swiss boys.
Rh, L., & Prader, A. (1983) · PubMed · Cited by 234
Long Term Outcome in Adult Males with Classic Congenital Adrenal Hyperplasia1
Cabrera, M. S., Vogiatzi, M. G., & New, M. I. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7668 · Cited by 204
Pubertal development in Swiss girls.
Largo, R. H., & Prader, A. (1983) · PubMed · Cited by 200
Eugster, E. A., DiMeglio, L. A., Wright, J. C., Freidenberg, G. R., Seshadri, R., & Pescovitz, O. H. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.110527 · Cited by 197
Adult Height and Fertility in Men with Congenital Virilizing Adrenal Hyperplasia
Urban, M. D., Lee, P. A., & Migeon, C. J. (1978) · New England Journal of Medicine · doi:10.1056/nejm197812212992505 · Cited by 196
Bonfig, W., Bechtold, S., Schmidt, H., Knorr, D., & Schwarz, H. P. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2109 · Cited by 167
Self-citationKlingensmith, G. J., Garcia, S. C., Jones, H. W., Migeon, C. J., & Blizzard, R. M. (1977) · The Journal of Pediatrics · doi:10.1016/s0022-3476(77)80581-7 · Cited by 163
Jääskeläinen, J., & Voutilainen, R. (1997) · Pediatric Research · doi:10.1203/00006450-199701000-00005 · Cited by 160
Congenital adrenal hyperplasia—a continuum of disorders
Hughes, I. A. (1998) · The Lancet · doi:10.1016/s0140-6736(98)22037-x · Cited by 141
Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience
Premawardhana, L. D. K. E., Hughes, I. A., Read, G. F., & Scanlon, M. F. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.1360962.x · Cited by 135
(1988) · PubMed · Cited by 110
Long Term Outcome in Adult Males with Classic Congenital Adrenal Hyperplasia
Cabrera, M. S. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.7.3070 · Cited by 105
Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients
Van der Kamp, H. J. (2002) · Archives of Disease in Childhood · doi:10.1136/adc.87.2.139 · Cited by 104
Balsamo, A., Cicognani, A., Baldazzi, L., Barbaro, M., Baronio, F., Gennari, M., Bal, M., Cassio, A., Kontaxaki, K., & Cacciari, E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030123 · Cited by 102
Pinto, G., Tardy, V., Trivin, C., Thalassinos, C., Lortat-Jacob, S., Nihoul-Fékété, C., Morel, Y., & Brauner, R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021433 · Cited by 101
Manoli, I., Kanaka‐Gantenbein, C., Voutetakis, A., Maniati‐Christidi, M., & Dacou‐Voutetakis, C. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01645.x · Cited by 100
Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
Flier, J. S., Underhill, L. H., Cutler, G. B., & Laue, L. (1990) · New England Journal of Medicine · doi:10.1056/nejm199012273232605 · Cited by 83
The effect of treatment of final height in classical congenital adrenal hyperplasia (CAH)
DiMartino-Nardi, J., Stoner, E., O'Connell, A., & New, M. I. (1986) · Acta Endocrinologica · doi:10.1530/acta.0.112s305 · Cited by 77
Hargitai, G., Sólyom, J., Battelino, T., Lebl, J., Pribilincová, Z., Hauspie, R., Kovács, J., Waldhauser, F., & Frisch, H. (2001) · Hormone Research in Paediatrics · doi:10.1159/000049990 · Cited by 76
Laue, L. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.10.3535 · Cited by 74
Stikkelbroeck, N. M. M. L., van’t Hof-Grootenboer, B. A. E., Hermus, A. R. M. M., Otten, B. J., & van’t Hof, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-030011 · Cited by 73
Muirhead, S. E., Sellers, E. A. C., & Guyda, H. J. (2002) · The Journal of Pediatrics · doi:10.1067/mpd.2002.126601 · Cited by 62
Growth and body proportions in congenital adrenal hyperplasia.
Young, M. C., Ribeiro, J., & Hughes, I. A. (1989) · Archives of Disease in Childhood · doi:10.1136/adc.64.11.1554 · Cited by 55
The Effect of Therapy on Mature Height in Congenital Adrenal Hyperplasia*
KIRKLAND, R. T., KEENAN, B. S., HOLCOMBE, J. H., KIRKLAND, J. L., & CLAYTON, G. W. (1978) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-47-6-1320 · Cited by 52
Yu, A., & Grant, D. (1995) · Acta Paediatrica · doi:10.1111/j.1651-2227.1995.tb13789.x · Cited by 52
Menarche and Subsequent Ovarian Function in Girls with Congenital Adrenal Hyperplasia
Hughes, I. A., & Read, G. F. (1982) · Hormone Research · doi:10.1159/000179489 · Cited by 43
Congenital Adrenal Hyperplasia: Lessons from a Multinational Study
Frisch, H., Waldhauser, F., Lebl, J., Solyom, J., Hargitai, G., Kovacs, J., Pribilincova, Z., Krzisnik, C., & Battelino, T. (2002) · Hormone Research in Paediatrics · doi:10.1159/000058109 · Cited by 33
Regulation of hypothalamic somatostatin by glucocorticoids
Devesa, J., Barros, M. G., Gondar, M., Tresguerres, J. A. F., & Arce, V. M. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00065-8 · Cited by 28
Einaudi, S., Lala, R., Corrias, A., Matarazzo, P., Pagliardini, S., & De Sanctis, C. (1993) · PubMed · Cited by 25
Acceptable linear growth in congenital adrenal hyperplasia
Duck, S. C. (1980) · The Journal of Pediatrics · doi:10.1016/s0022-3476(80)80141-7 · Cited by 11
Cited by
Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769
“In patients with CAH, glucocorticoid dosages exceeding 20 mg/m(2)/d in infants and 15 to 17 mg/m(2)/d in adolescents have been shown to result in loss of height and shorter adult stature (124, 125).”
BackgroundSpeiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Merke, D. P., & Auchus, R. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1909786 · Cited by 341
PW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
Metadata
- Authors
- Bonfig, W., Dalla Pozza, S. B., Schmidt, H., Pagel, P., Knorr, D., & Schwarz, H. P.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- University Children’s Hospital (W.B., S.B.D.P., H.S., D.K., H.P.S.), Ludwig Maximilians University, Division of Pediatric Endocrinology, D-80337 Munich, Germany
- Technical University of Munich (DE)
- Corresponding author
- Bonfig, Walter
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-10-01
- Volume
- 94
- Issue
- 10
- Pages
- 3882-3888
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2020519708
- Cited by
- 136
- References
- 41
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 9 · 2023: 9 · 2022: 9 · 2021: 7 · 2020: 2 · 2019: 9 · 2018: 7 · 2017: 5 · 2016: 12 · 2015: 7 · 2014: 6 · 2013: 10 · 2012: 3
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- classical congenital adrenal hyperplasia, puberty, pubertal growth, adult height, glucocorticoid therapy, salt-wasting CAH, simple virilizing CAH, short stature, dose-response relationship, children, adolescents, growth inhibition, pediatric endocrinology
- MeSH terms
- Adolescent, Adrenal Hyperplasia, Congenital, Body Height, Child, Drug Administration Schedule, Female, Humans, Hydrocortisone, Male, Puberty, Puberty, Precocious, Retrospective Studies, ROC Curve, Logistic Models, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.